51 results about "Carcinoma in situ" patented technology

The present invention relates to an immunofluorescence kit for detecting PD-L1 and CD8 antigens and a detection method using the kit. The kit comprises the following reagents: buffer solutions CYP1, CYP2 and CYPP, a blocking solution, a specific antibody for detecting PD-L1, a corresponding fluorescent second antibody, a fluorescently labeled CD45 antibody, a fluorescently labeled CD8 antibody, anantibody dilution solution and a nuclear staining solution. The invention also provides a method for carrying out antigen detection by using the kit. A detection result of the kit can guide actual drug use, and not only can reflect the whole tumor comprising carcinoma in situ and possibly existent invisible micro-metastasis load, but also can reflect the expression condition of the PD-L1 in CTC;a reference can be provided for precise selection of therapeutic drugs according to the proportion of PD-L1 and CD8 positive cells in PBMC; and the kit is more convenient than a detection technology based on tumor tissues in material acquisition.

MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis.

A system (40) for diagnosis and staging of early stages of cancer in the tissue of a patient is provided. The system is configured to combine information from a Polarized Light Scattering Spectroscopy measurement (70) having a first probe depth, and a Differential Path Length Spectroscopy measurement (60) having a second probe depth, wherein the second probe depth is set larger than' the first probe depth. By comparing the results of the Polarized Light Scattering Spectroscopy and Differential Path Length Spectroscopy measurements early stages of cancer, such as dysplasia may be detected. Also hyperplasia, carcinoma in situ, and carcinoma may be detected. A computer-readable medium, method and use are also provided.

The invention relates to photosensitizer sodium chlorophyllin derivatives and their preparation method and novel use in preparation of drugs for treating tumors and especially in preparation of a photosensitizer drug for photodynamic treatment on the bladder cancer. The photosensitizer sodium chlorophyllin derivatives comprise sodium chlorophyllin e4, sodium chlorophyllin e6 and sodium chlorophyllin f compounds shown in the structural formula. An in-vitro human bladder cancer killing effect test on sodium chlorophyllin proves that the photosensitizer sodium chlorophyllin derivatives have obvious effects of killing tumor cells, good effects of treating bladder carcinoma in situ and intractable and repeated superficial bladder cancer, low toxicity and high safety, avoids operation in a dark place in treatment, has a unique advantage and provides an experiment basis for clinic application.

An improved autovaccination method designed to prevent or treat various neoplastic diseases by inducing a systemic immune response against a tumor and its remote metastases, consisting of the induction of an immunogenic cell death in one or more targeted tumor sites with local radiation therapy, cryotherapy, heat, chemotherapy or various other treatments, followed by intratumoral / peritumoral injection of dsRNAs (poly-ICLC in particular) in the same tumor site.

Described herein are progenitor cancer cells and cell lines isolated from human breast ductal carcinoma in situ (DCIS) lesions and the uses of these cells or cell lines in drug design, drug screening, and monitoring in vivo therapy. The DCIS malignant precursor cells or cell lines are epithelial in origin, are positive for markers of autophagy, show at least one genetic difference from normal cells of said fragment, form 3-D tube-like structures or ball aggregates, or are inhibited in formation of 3-D structures and migration by treatment with chloroquine. In one embodiment, there is a loss of heterozygosity (LOH) that is narrowly confined to a region of chromosome 6p (6p21.1-6p12.3) that contains the SUPT3H gene.

The invention discloses an elastic targeting polypeptide-based medicine-carrying nanoparticle. The nanoparticle is prepared from an elastic targeting polypeptide and a modified medicine, wherein the modified medicine is a modified paclitaxel PTX-LEV-MECH or modified salinomycin Sail-ABA-MPBH. The elastic targeting polypeptide-based medicine-carrying nanoparticle provided by the invention is 100nmor below in particle size, so that the dispersion degree is low, the medicine carrying rate is high, and the nanoparticle can be combined with in-vivo albumin for transferring and carrying medicine, and also can be combined with acidic rich cysteine specifically secreted by tumor cells, the drug is concentrated in the acidic environment, the breast cancer in-situ cancer is targeted for killing, and the toxic and side effects of the drug on the whole body are reduced; and the efficacy of treating breast cancer is increased and improved by utilizing the synergistic effect of two nanoparticles, the occurrence of the metastasis of the breast cancer cells through a lymphatic system and a blood system is reduced, and the occurrence of serious complications such as medical-source lymphatic edemacaused by a lymph node sweeping surgery is reduced.

MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis.

The invention discloses a method for establishing a model of oral cancer and lymphatic metastasis of mice, which is characterized by including mouse selection and grouping, reagent preparation, mouse feeding, experimental observation and conclusion drawing. The method specifically includes: using 200mg / L 4-nitroquinoline-1-oxide to feed Balb / c (Bagg albino / c) mice for 20 weeks by a drinking method; continuously using tap water to feed the mice to the fortieth week and observing to the fortieth week; obtaining the model of oral cancer and lymphatic metastasis of the mice which have development metastasis extremely similar to human oral cancer, namely location diversification, a full metastasis process of normal mucosa, dysplasia, carcinoma in situ, squamous carcinoma and cervical lymph nodes. The method is simple, natural and ideal in effect, guarantees high morbidity, diversified disease locations (lip, palate, gum, tongue and mouth floor) and high submandibular lymph node metastasis rate, and a novel powerful tool for preventing and treating human oral cancer is provided.

The present invention provides a method for screening anti-breast cancer metastasis compounds by using a tumor metastasis gene map. The method comprises: randomly selecting at least one gene from 18 genes such as MMP1, FSCN1, PTGS2, EREG, ANGPTL4, VCAM1, CXCR4, CXCL1, RARRES3, ID1, TNC, LY6E, LTBP1, C10orf116, KRTHB1, KYNU, MAN1A1 and NEDD9; and designing probes, and selecting compounds for converting the expression levels of the genes in breast cancer cells after metastasis to the expression levels of the genes in in-situ carcinoma cells or normal cells. According to the present invention, the 20 compounds are selected through the method, and the cytological level and animal level experiment results demonstrate that the compounds or the combinations thereof exhibit the anti-breast cancermetastasis activity to different degrees.

The invention discloses a model in vitro which can simulate the metastasis of human liver cancer dynamically. The construction steps comprise the construction of an anti-cell adherence model by using human liver cancer cell line BEL7402 with high metastasis; the construction of metastasis model in vitro of liver cancer cell and the identification for the constructed in vitro metastasis model of liver cancer. The model of the invention can be used for the control research between the in situ cancer and the tumor in metastasis; the invention can further be used as a monitoring system for the biological behavior detection of the tumor cell in metastasis and the judgment of tumor prognosis. The model has important value for the research of clinical tumor metastasis mechanism and the screening of metastasis control drugs. The model can also be used as the screening technology platform for the preparation of anti-tumor transgenic vaccine and the construction of anti-tumor metastasis drugs.

The invention discloses a cancer shifting and finding method of different classifications and phases, whatever the cancer is relative to the Ibo-virus, which analyzes individual plasma or Ibo-virus DNA level in the serum once or several times continuously.

A multimodal ultrasound / photoacoustic tumor margin detection system. The system can be comprised of an imaging and system control console, which can include an ultrasound and data acquisition subsystem including an ultrasound transmitter and receiver configured to transmit and receive ultrasonic energy. A host-control computer configured to provide a function generator function and a delay generation function can also be a part of the imaging and system control console.

The invention discloses an application of a proteasome inhibitor in anti-cancer drugs. The proteasome inhibitor comprises Carfilzomib (carfilzomib), Bortezomib (bortezomib), MLN9708 (ixazomib), MG132and the like. The targeted cancer is a cancer in which macrophage polarization participates, i.e., a tumor in which the macrophage type is mainly M2 type in a tumor microenvironment, including a solidtumor and a hematologic tumor, and also including an in-situ cancer and a transplanted cancer. It is found through a large amount of creative work that the proteasome inhibitor converts M2 type TAM in the tumor immune microenvironment into M1 type TAM, thereby improving the tumor microenvironment, promoting the phagocytic effect of macrophages on tumor cells and increasing infiltration of immunecells on tumors to inhibit tumor growth.

The invention provides a use of an AKR1B10 (aldo-keto reductase family 1 B10) gene protein as a breast cancer diagnostic marker and a drug target, and discloses an AKR1 B10 gene protein as a diagnostic marker of HER2 (human epidermal growth factor receptor 2) high expression breast cancer and a drug target for the pathologic diagnosis and therapeutic target of breast cancer. The expression of the AKR1 B10 gene protein in ductal carcinoma in situ (DCIS) of breast is in positive correlation with HER2 expression and is in negative correlation with ER (estrogen receptor) expression.

The invention provides application of a known chemical compound to preparing medicines for treating tumor, and discloses an anticancer agent. The anticancer agent has the advantages that effects of suppressing carcinoma in situ or metastatic carcinoma of diversified systems such as nervous systems, digestive systems, genitourinary systems, skin, bone and joint systems, respiratory systems and blood and gland systems can be realized by the anticancer agent; effects of suppressing benign and malignant tumor can be realized by the anticancer agent; the anticancer agent is safe, is free of toxicity and can be hopefully newly widely applied to the fields of healthcare foods and medicines.

The present invention is one novel medicine package for preventing and treating women's cervical virus infection, and the medicine package has novel medicine recipe, novel medicine form and novel medicine transfer device. The medicine package is for treating chronic cervicitis caused by sexually transmitted cervical human papilloma virus (HPV), herpes simplex virus II (HSV-2), cytomegalovirus (CMV), etc and cervical epithelium maldevelopment. It has the functions of inhibiting virus propagation and preventing cervical carcinoma. The present invention has unique medicine recipe, special medicine transfer mode, accurate administration to the pathological cervical part, high local medicine concentration, lasting medicine action period and raised antiviral effect. The cervical Papanicolaou smear examination reveals that the present invention is advance and effective.

The present invention relates to the field of diagnostic and therapeutic use of proteins and genes, in particular to the diagnostic and therapeutic use of a secreted human hormone / growth factor, Neublasmin, and use or the gene coding for Neublasmin in the diagnosis and treatment of testicular disorders, in particular diagnosis and treatment of germ cell tumours and infertility. The invention also relates to use of Neublasmin in the treatment of CNS disorders. Neublasmin is expressed at high levels in human adult testicles and in developing mouse testicles from pn 22 and onwards. Expression or Neublasmin is strongly up-regulated in carcinoma in situ. Expression is also seen in foetal and adult brain.

Devices, systems and methods are provided for treating conditions of the reproductive tract. A number of conditions can afflict the lining and cell layers deeper within the anatomical structures. For example, cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is a condition involving abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer in situ (CIS). Other conditions include human papillomavirus (HPV)-related cervical disease, various endometrial diseases, acute and chronic cervicitis, and various infections (e.g. trichomoniasis) to name a few. In some embodiments, treatments eliminate diseased, damaged, abnormal or otherwise undesired cells leaving the tissue framework intact. This allows the tissue to regenerate in a normal fashion, avoiding the formation of scar tissue. When the tissue framework is left intact, the framework structure repopulates with healthy cells, regenerating the normal tissue without altering the structural properties.

The invention relates to the field of proteins, in particular to application of recombinant human calcineurin B subunit, and mainly provides application of rhCNB to preparation of a medicine for killing and / or inhibiting a gastric cancer cell MGC-803. When rhCNB for injection plays a role in treatment of human gastric cancer cell MGC-803 carcinoma in situ transplantation tumors in BALB / c nude mice, the effective tumor treatment (compared with that of a solvent control group, p is smaller than 0.05) time starts after continuous medication for 6 times; in the whole medication process, the tumors can be effectively controlled; one week after medicine withdrawal, rhCNB for injection still has a continuous and effective treating effect (compared with that of the solvent control group, p is smaller than 0.001) on the tumors; the performance of rhCNB for injection is superior to those of cisplatin for positive control injection and hydroxycamptothecine for injection, and equivalent to recombinant human interleukin-2 for injection.

The invention discloses a method for constructing an in vitro model with dynamic simulation of hepatoma metastasis of human beings, comprising construction of a cell attachment resistant model, construction of the hepatoma cell in vitro metastasis model, identification of the constructed hepatoma in vitro metastasis model, etc. The method of the invention applies high metastasis tendency BEL7402 hepatoma cells to simulate and construct the in vitro model for hepatoma cell metastasis by constructing a model which makes the BEL7402 hepatoma cells deviated from attachment of extracellular matrixes and simulating a condition that transitional cells grows by means of anchorage dependence again when meeting adequate environment. By utilization of the model, control study of carcinoma in situ and tumor during the metastatic process can be performed, and the model can be further taken as a monitoring system for detecting biological behaviors of tumor cells during the metastatic process and judging tumor prognosis. The model has important value in researching a clinical tumor metastatic mechanism and controlling screening of metastasis drugs and also can be taken as a platform for preparing tumor metastasis resistant gene vaccine and establishing a tumor metastasis resistant drug screening technology.

The invention discloses a model in vitro which can simulate the metastasis of human neuroglioma dynamically. The construction steps comprise the construction of an anti-cell adherence model by using human neuroglioma cell line U251; the construction of in vitro metastasis model of human neuroglioma cell and the identification for the constructed metastasis model in vitro of human neuroglioma. The model of the invention can be used for the control research between the in situ cancer and the tumor in metastasis; the invention can further be used as a monitoring system for the biological behavior detection of the tumor cell in metastasis and the judgment of tumor prognosis. The model has important value for the research of neuroglioma metastasis mechanism and the screening for metastasis control drugs. The model can also be used as the screening technology platform for the preparation of anti-neuroglioma transgenic vaccine and the construction of anti-tumor metastasis drugs.

The invention relates to photosensitizer sodium chlorophyllin derivatives and their preparation method and novel use in preparation of drugs for treating tumors and especially in preparation of a photosensitizer drug for photodynamic treatment on the bladder cancer. The photosensitizer sodium chlorophyllin derivatives comprise sodium chlorophyllin e4, sodium chlorophyllin e6 and sodium chlorophyllin f compounds shown in the structural formula. An in-vitro human bladder cancer killing effect test on sodium chlorophyllin proves that the photosensitizer sodium chlorophyllin derivatives have obvious effects of killing tumor cells, good effects of treating bladder carcinoma in situ and intractable and repeated superficial bladder cancer, low toxicity and high safety, avoids operation in a dark place in treatment, has a unique advantage and provides an experiment basis for clinic application.

The invention relates to a novel anti-tumor epirubicin compound being an epirubicin hydrochloride v-type compound, wherein the novel compound is easy to prepare and has advantages of less hygroscopicity, improved storage stability, good promotion of drug quality control and the like. The novel anti-tumor epirubicin compound is used for application in treatment and preventive drugs for treatment ofthe malignant lymphomam, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia, and brain glioma, treatment of the superficial bladder cancer and carcinoma in situ by the intravesical administration, and prevention of recurrence after transurethral resection and the like.

A method of differentiating among the presence of ductal carcinoma in situ in the breast, benign fibroadenoma of the breast, and non-cancerous breast tissue in a subject is disclosed. The method comprises: measuring the concentration of at least one protein biomarker selected from a group of forty-nine differentially expressed proteins in the saliva of persons with DCIS, or benign fibroadenoma, or in persons who are cancer-free. The resulting test data is compared to a reference panel. From the comparison the presence in the subject of either ductal carcinoma in situ of the breast, or benign fibroadenoma of the breast is determined.

The invention relates to a key CT technology of a lung carcinoma in-situ identification method. The key CT technology of the lung carcinoma in-situ identification method comprises an ultra-high resolution CT, a multi-position imaging technology, a target scanning technology and a combined image processing technology. The key CT technology has the advantages that target reconstruction is carried out unlike on an original data image obtained by conventional scanning, target scanning is not a simple geometric enlargement, and the image is clearer; instead, the target scanning is based on ultra-high resolution CT, multi-position imaging is achieved, the obtained image is enabled to be clearer, and the internal microstructure, density, border and surrounding signs of small nodules can be clearly showed; and moreover, ultra-high resolution combined with the multi-position imaging technology and the target scanning technology can analyze the characteristic imaging findings of ground glass nodules in shape, edge, density, diameter, internal solid components, vascular abnormalities and pleural depression, and early accurate diagnosis is expected to be performed on AAH and AIS and further guide clinical practice.

The invention relates to the technical field of breast cancer detection, in particular to an auxiliary mammary duct in-situ cancer detection system which comprises a slice sampling device, a photographing unit, a storage module and an analysis module. The slice sampling device comprises a sampling vessel, a slice disc and a controller; due to the fact that IDC and DCIS have high similarity in thecellular morphology, the accuracy of distinguishing by directly utilizing a convolutional neural network algorithm from the cellular morphology is not high, and then the accuracy of DCIS detection isaffected. Therefore, through the slice disc arranged in the sampling vessel and the temperature control effect of the semiconductor chilling plate in the slice disc, the cell tissues in the sampling vessel are continuously made into pathological slices by the slicing knife in the slice groove, frozen and shaped in the slice disc to obtain a large number of pathological slices, and the pathologicalslices are provided for the analysis module for image recognition; and comprehensive analysis on pathological sections of cell tissues is achieved, so that the application effect of the auxiliary detection system for the breast duct in-situ cancer is improved.

An exemplary system, method and computer-accessible medium for determining ductal carcinoma in situ (DCIS) information regarding a patient(s) can include for example, receiving image(s) of internal portion(s) of a breast of the patient(s), and automatically determining the DCIS information by applying a neural network(s) to the image(s). The DCIS information can include predicting (i) pure DCIS or (ii) DCIS with invasion. Input information of the patient(s) can be selected for a DCIS observation for determining the DCIS information. The image(s) can be a mammographic image(s). The image(s) can be one of a magnetic resonance image or a computer tomography image.

HER2+ invasive breast cancer (IBC) patients with residual disease following neoadjuvant chemotherapy have an anti-HER2 Type 1 T helper (Th1) cell immune deficit and a significant risk of recurrent disease. It has been shown that anti-HER2 CD4+ T-cell responses incrementally decrease along the breast cancer continuum - a robust response in healthy donors and patients with benign disease, a depressed response in patients with HER2+ ductal carcinoma in situ, and a nearly absent response in patients with HER2+ IBC. This invention relates to a method of creating a microenvironment for culture expansion of T cells. The expanded T cells can be used for a variety of therapeutic and research purposes.